A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Latest Information Update: 12 May 2023
Price :
$35 *
At a glance
- Drugs Brodalumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms AMAGINE-3
- Sponsors Amgen; Bausch Health Companies
- 21 Mar 2023 Results of post hoc analysis of AMAGINE 2 and AMAGINE 3 evaluating long term efficacy of brodalumab stratified by onset of treatment response, presented at the American Academy of Dermatology annual Meeting 2023
- 01 Aug 2022 Results evaluating the efficacy response rates and safety outcomes through 120 weeks from post hoc pooled analysis from AMAGINE-2 and -3 studies, published in the Journal of the European Academy of Dermatology and Venereology.
- 01 Feb 2022 Results assessing efficacy of brodalumab in patients with nail or scalp psoriasis in three phase 3 studies (AMAGINE-1/-2/-3), published in the Journal of Dermatological Treatment.